未登录 Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study FGFR3突变型晚期尿路上皮癌中，erdafitinib在enfortumab vedotin治疗前或治疗后的疗效：UNITE协作研究的分析 Jiang, Cindy Y.; Hwang, Hyunsoo; Epstein, Ilana Y.; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Taylor, Amy K.; Nizam, Amanda; Jindal, Tanya; Glover, Michael J.; Khaki, Ali Raza; Barata, Pedro C.; Nguyen, Charles B.; Oh, Eugene; Davis, Nancy B.; Mabey, Hannah; Hoimes, Christopher J.; Evans, Sean T.; Abuqayas, Bashar; Lemke, Emily; Tsung, Irene; Qiao, Wei; Kilari, Deepak; Zakharia, Yousef; Bilen, Mehmet A.; Milowsky, Matthew, I; Shah, Sumit A.; Gupta, Shilpa; Emamekhoo, Hamid; Bellmunt, Joaquim; Alva, Ajjai S.; Grivas, Petros; Msaouel, Pavlos; Koshkin, Vadim S.; Campbell, Matthew T.; Alhalabi, Omar 分享 收藏
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study 接受恩沃利单抗维多汀治疗的晚期尿路上皮癌患者中的治疗相关不良事件及关联结局：UNITE研究的分析 Nizam, Amanda; Nguyen, Charles B.; Li, Jinju; Zabor, Emily C.; Msaouel, Pavlos; Jiang, Cindy Y.; Alhalabi, Omar; Oh, Eugene; Davidsohn, Matthew P.; Epstein, Ilana B.; Bakaloudi, Dimitra Rafailia; Talukder, Rafee; Jindal, Tanya; Taylor, Amy K.; Glover, Michael J.; Khaki, Ali Raza; Lemke, Emily; Mabey, Hannah; Abuqayas, Bashar; Jang, Albert; Brown, Jason R.; Evans, Sean T.; Pywell, Cameron; Basu, Arnab; Bilen, Mehmet A.; Barata, Pedro C.; Zakharia, Yousef; Milowsky, Matthew I.; Kilari, Deepak; Hoimes, Christopher J.; Shah, Sumit A.; Emamekhoo, Hamid; Davis, Nancy B.; Gupta, Shilpa; Grivas, Petros; Bellmunt, Joaquim; Campbell, Matthew T.; Alva, Ajjai S.; Koshkin, Vadim S. 分享 收藏
A Phase 1, multiple-dose study to evaluate the safety and tolerability of first-in-class XmAb819 (ENPP3 x CD3) in subjects with relapsed or refractory clear cell renal cell carcinoma (ccRCC) (NCT05433) 一项I期、多次给药研究，旨在评估首创新药XmAb819 (ENPP3 x CD3)在复发或难治性透明细胞肾细胞癌（ccRCC）受试者中的安全性与耐受性（NCT05433）。 Bohac, Chet; Pal, Sumanta; Sweis, Randy; Kotecha, Ritesh; Runcie, Karie; Bilen, Mehmet; Braun, David; Tykodi, Scott; Hoimes, Christopher; Suri, Vithika; Kanodia, Jitendra; Salama, Engie; Woo, Jacky; Li, Lingling; Yang, Yuanquan; Franklin, Robert; Maly, Joseph; Grigg, Claud; Gulati, Shuchi; Vanderweele, David J.; Garmezy, Benjamin 分享 收藏
分享 收藏
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma I期b/II期研究：评估batiraxcept单药及联合cabozantinib（无论是否联合nivolumab）治疗晚期透明细胞肾细胞癌的疗效。 Beckermann, Kathryn E.; Shah, Neil J.; Campbell, Matthew T.; Haas, Naomi B.; Nelson, Ariel; Ornstein, Moshe C.; Mao, Shifeng; Keshava-Prasad, Holavanahalli S.; Hammers, Hans; Gao, Xin; Gourdin, Theodore; George, Saby; Hoimes, Christopher J.; Hussain, Arif; Jonasch, Eric; Rini, Brian, I; Voss, Martin H. 分享 收藏
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data 与恩夫妥单抗韦汀疗效相关的基因组生物标志物：对UNITE研究数据的分析 Jindal, Tanya; Jiang, Cindy; Alhalabi, Omar; Nizam, Amanda; Nguyen, Charles; Talukder, Rafee; Bakaloudi, Dimitra; Davidsohn, Matthew; Freeman, Dory; Glover, Michael; Khaki, Ali Raza; Evans, Sean; Lemke, Emily; Bose, Rohit; Sim, Woogwang; Pywell, Cameron; Basu, Arnab; Kilari, Deepak; Barata, Pedro C.; Bilen, Mehmet A.; Zakharia, Yousef; Milowsky, Matthew I.; Shah, Sumit A.; Bellmunt, Joaquim; Grivas, Petros; Emamekhoo, Hamid; Davis, Nancy B.; Gupta, Shilpa; Hoimes, Christopher; Campbell, Matthew T.; Alva, Ajjai; Koshkin, Vadim S. 分享 收藏
Preliminary safety and anti-tumor activity of TYRA-300, a highly selective FGFR3 inhibitor, in participants with advanced solid tumors with activating FGFR3 mutations/fusions (SURF301) Tran, B.; Boni, A.; Hansen, A.; Boni, V.; Mantia, C.; Yu, E.; Weickhardt, A.; Robert, M.; Gupta, S.; Necchi, A.; Morales-Barrera, R.; Hoimes, C.; Berlin, J.; Iyer, G.; Millward, M.; Burn, T.; Lihou, C.; Gammon, G.; Rosenberg, J.; Loriot, Y. 分享 收藏
A Multicenter, Open-label Phase 1/2 Study of TYRA 300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF301) Zhang, A.; Boni, V.; Hanson, A.; Mantia, C.; Weickhardt, A.; Yu, E.; Gupta, S.; Robert, M.; Iyer, G.; Millward, M.; Morales-Barrera, R.; Hoimes, C.; Berlin, J.; Mittal, K.; Hill, A.; Racca, F.; Pouessel, D.; Lihou, C.; Tran, B.; Loriot, Y. 分享 收藏
Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE 恩沃利单抗 vedotin（Enfortumab vedotin）诱导的外周神经病变（EVIPN）在晚期尿路上皮癌（aUC）患者中的预处理（Tx）危险因素：UNITE 分析 Nizam, A.; Zhang, L.; Jiang, C. Y.; Nguyen, C. B.; Bakaloudi, D. R.; Bilen, M. A.; Barata, P. M. Coelho; Zakharia, Y.; Milowsky, M. I.; Kilari, D.; Hoimes, C. J.; Khaki, A. R.; Emamekhoo, H.; Gupta, S.; Grivas, P.; Bellmunt, J.; Alva, A. S.; Campbell, M. T.; Alhalabi, O.; Koshkin, V. S. 分享 收藏
Efficacy of enfortumab vedotin (EV) in patients (pts) with (w) advanced urothelial carcinoma (aUC) who have baseline neuropathy (N) and/or diabetes mellitus (DM): A UNITE study analysis 恩诺妥昔单抗（EV）在具有基线神经病变（N）和/或糖尿病（DM）的晚期尿路上皮癌（aUC）患者（pts）中的疗效：一项UNITE研究的分析 Jang, A.; Jindal, T.; Jiang, C. Y.; Nguyen, C. B.; Nizam, A.; Alva, A. S.; Grivas, P.; Bellmunt, J.; Hoimes, C. J.; Bilen, M. A.; Emamekhoo, H.; Milowsky, M. I.; Khaki, A. R.; Gupta, S.; Campbell, M. T.; Alhalabi, O.; Chen, Z.; Fu, P.; Koshkin, V. S.; Brown, J. R. 分享 收藏
Enfortumab vedotin (EV) plus pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study 恩福妥单抗（EV）联合帕博利珠单抗（P）在临床试验外的疗效及在晚期尿路上皮癌患者（pts）中的获益生物标志物：UNITE研究的分析 Jindal, T.; Jiang, C. Y.; Alhalabi, O.; Tsung, I.; Jang, A.; Bakaloudi, D. R.; Sidhom, F.; Taylor, A. K.; Hoimes, C. J.; Bellmunt, J.; Bilen, M. A.; Gupta, S.; Milowsky, M. I.; Shah, S.; Basu, A.; Grivas, P.; Brown, J. R.; Campbell, M. T.; Alva, A. S.; Koshkin, V. S. 分享 收藏
Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) plus pembrolizumab (P) in cisplatin (CIS)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) 研究EV-103剂量递增/队列A（DE/A）：在不可接受顺铂治疗的局部晚期或转移性尿路上皮癌（la/mUC）中，恩沃利单抗偶联物（EV）联合帕博利珠单抗（P）的一线（1L）5年随访研究 Rosenberg, J. E.; Petrylak, D. P.; Flaig, T.; Hoimes, C. J.; Gupta, S.; O'Donnell, P. H.; Mar, N.; Friedlander, T.; Tagawa, S. T.; Bilen, M. A.; Brown, J. R.; McKay, R. R.; Merchan, J. R.; Srinivas, S.; Shetty, A.; Homet Moreno, B.; Davis, G.; Wirtz, H.; Zhu, Y.; Milowsky, M. I. 分享 收藏
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study Pembrolizumab联合enzalutamide治疗转移性去势抵抗性前列腺癌在enzalutamide治疗进展: 2期主题199研究的队列4和5 Graff, Julie N.; Hoimes, Christopher J.; Gerritsen, Winald R.; Vaishampayan, Ulka N.; Elliott, Tony; Hwang, Clara; ten Tije, Albert J.; Omlin, Aurelius; McDermott, Raymond S.; Fradet, Yves; Tagawa, Scott T.; Kilari, Deepak; Ferrario, Cristiano; Uemura, Hiroji; Jones, Robert J.; Fukasawa, Satoshi; Peer, Avivit; Niu, Cuizhen; Poehlein, Christian H.; Qiu, Ping; Suttner, Leah; de Wit, Ronald; Schloss, Charles; de Bono, Johann S.; Antonarakis, Emmanuel S. 分享 收藏
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma Sitratinib联合Nivolumab治疗晚期或转移性尿路上皮癌患者的2期研究 Msaouel, Pavlos; Sweis, Randy F.; Bupathi, Manojkumar; Heath, Elisabeth; Goodman Jr, Oscar B.; Hoimes, Christopher J.; Milowsky, Matthew I.; Davis, Nancy; Kalebasty, Arash Rezazadeh; Picus, Joel; Shaffer, David; Mao, Shifeng; Adra, Nabil; Yorio, Jeffrey; Gandhi, Sunil; Grivas, Petros; Siefker-Radtke, Arlene; Yang, Rui; Latven, Lisa; Olson, Peter; Chin, Curtis D.; Der-Torossian, Hirak; Mortazavi, Amir; Iyer, Gopa 分享 收藏
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study Fletcher, Kylie; Cortellini, Alessio; Ganta, Teja; Kankaria, Roma; Song, Haocan; Ye, Fei; Irlmeier, Rebecca; Debnath, Neha; Saeed, Anwaar; Radford, Maluki; Alahmadi, Asrar; Diamond, Akiva; Hoimes, Christopher; Presley, Carolyn J.; Owen, Dwight H.; Abou Alaiwi, Sarah; Nassar, Amin H.; Lamberti, Giuseppe; Perrone, Fabiana; Buti, Sebastiano; Giusti, Raffaele; Filetti, Marco; Vanella, Vito; Mallardo, Domenico; Sussman, Tamara A.; Galetta, Domenico; Kalofonou, Foteini; Daniels, Ella; Ascierto, Paolo A.; Pinato, David J.; Nebhan, Caroline; Berg, Stephanie; Choueiri, Toni K.; Marron, Thomas U.; Wang, Yinghong; Naqash, Abdul Rafeh; Johnson, Douglas B. 分享 收藏
分享 收藏
Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132) Izar, Benjamin; Zamarin, Dmitriy; Spigel, David R.; Hoimes, Christopher J.; McDermott, David F.; Sehgal, Kartik; Najjar, Yana G.; Schoenfeld, Adam J.; Garon, Edward B.; Sullivan, Ryan J.; Henick, Brian S.; Leal, Ticiana A.; Hurwitz, Michael E.; McKay, Rana R.; Busby, Natalie; Mehta-Damani, Anita; Azrilevich, Alex; Tran, Tony; Rizvi, Naiyer; Oft, Martin; Spira, Alexander I. 分享 收藏
Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer Seguier, Denis; Adams, Eric S.; Kotamarti, Srinath; D'Anniballe, Vincent; Michael, Zoe D.; Deivasigamani, Sriram; Olivier, Jonathan; Villers, Arnauld; Hoimes, Christopher; Polascik, Thomas J. 分享 收藏
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab 探索未经治疗的局部晚期或转移性尿路上皮癌的新治疗组合: enfortumab vedotin加pembrolizumab Hoimes, Christopher J.; Flaig, Thomas W.; Milowsky, Matthew, I; Friedlander, Terence W.; Bilen, Mehmet Asim; Gupta, Shilpa; Srinivas, Sandy; Merchan, Jaime R.; Mckay, Rana R.; Petrylak, Daniel P.; Sasse, Carolyn; Moreno, Blanca Homet; Yu, Yao; Carret, Anne-Sophie; Rosenberg, Jonathan E. 分享 收藏
Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy Shah, N. J.; Campbell, M. T.; Mao, S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H.; Keshava-Prasad, H.; Hoimes, C. J.; Hussain, A.; George, S.; Gourdin, T. S.; Nelson, A.; Yan, H.; Esquibel, V.; McIntyre, G.; Geller, R.; Voss, M. H.; Rini, B. I.; Beckermann, K. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ONCOLOGIST.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏